| Autor: |
Frank S; Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Ave., Kirstein 228, Boston, MA, 02215, USA. sfrank2@bidmc.harvard.edu., Anderson KE; Georgetown University, Washington, DC, USA., Fernandez HH; Cleveland Clinic, Cleveland, OH, USA., Hauser RA; University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL, USA., Claassen DO; Vanderbilt University Medical Center, Nashville, TN, USA., Stamler D; Teva Branded Pharmaceutical Products R&D, Inc., La Jolla, CA, USA., Factor SA; Emory University, Atlanta, GA, USA., Jimenez-Shahed J; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Barkay H; Teva Pharmaceutical Industries Ltd., Netanya, Israel., Wilhelm A; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Alexander JK; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Chaijale N; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Barash S; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Savola JM; Teva Pharmaceuticals International GmbH, Basel, Switzerland., Gordon MF; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Chen M; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA. |
